• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与良性前列腺增生患者相比，前列腺癌患者中 IL-10+CD19+B 细胞的频率。

Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia.

机构信息

Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Department of Pathology, Shahrekord University of Medical Sciences, Shahrekord, Iran.

出版信息

Afr Health Sci. 2020 Sep;20(3):1264-1272. doi: 10.4314/ahs.v20i3.31.

DOI:10.4314/ahs.v20i3.31
PMID:33402974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7751534/
Abstract

BACKGROUND

The function of the immune system in prostate cancer (PC) might promote carcinogenesis. PC is a common cancer in men. Regulatory B cells (Bregs) are a new subtype of B cells that have suppressive roles in the immune system. Interleukin-10 (IL-10) is a dominant mediator of immune suppression released by Bregs.

OBJECTIVE

The purpose of this research was to examine the frequency of CD19+IL10+ B cells and IL-10 mRNA expression in patients with PC compared to patients with benign prostatic hyperplasia (BPH).

METHODS

Forty paraffin tissue samples from patients with PC and 32 paraffin tissue samples from patients with BPH were entered in this study. The immunohistochemistry staining was used to evaluate the pattern expression of CD19 and IL-10 markers. IL-10 mRNA expression in fresh tissue was determined by real time-polymerase chain reaction (RT-PCR).

RESULTS

The frequency of CD19+IL-10+ B cells and IL-10 mRNA expression in PC patients were significantly higher than patients with BPH. Also, there was no meaningful relationship between the frequency of IL-10+CD19+ B cells and gleason scores in patients with PC.

CONCLUSIONS

Our findings suggested that frequency of IL-10+CD19+ B cells correlates with progressive stage of PC.

摘要

背景

免疫系统在前列腺癌（PC）中的功能可能促进癌发生。PC 是男性常见的癌症。调节性 B 细胞（Bregs）是 B 细胞的一个新亚型，在免疫系统中具有抑制作用。白细胞介素 10（IL-10）是 Bregs 释放的主要免疫抑制介质。

目的

本研究旨在检测与良性前列腺增生（BPH）患者相比，PC 患者中 CD19+IL10+B 细胞和 IL-10mRNA 表达的频率。

方法

本研究纳入了 40 例 PC 患者和 32 例 BPH 患者的石蜡组织样本。采用免疫组织化学染色法评估 CD19 和 IL-10 标志物的表达模式。通过实时聚合酶链反应（RT-PCR）测定新鲜组织中 IL-10mRNA 的表达。

结果

PC 患者中 CD19+IL10+B 细胞的频率和 IL-10mRNA 表达明显高于 BPH 患者。此外，PC 患者中 IL-10+CD19+B 细胞的频率与 Gleason 评分之间无明显关系。

结论

我们的研究结果表明，IL-10+CD19+B 细胞的频率与 PC 的进展阶段相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/7203c3026265/AFHS2003-1264Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/0f8c26a09995/AFHS2003-1264Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/2104c43f39ed/AFHS2003-1264Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/7203c3026265/AFHS2003-1264Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/0f8c26a09995/AFHS2003-1264Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/2104c43f39ed/AFHS2003-1264Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8022/7751534/7203c3026265/AFHS2003-1264Fig3.jpg

相似文献

1
Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia.与良性前列腺增生患者相比，前列腺癌患者中 IL-10+CD19+B 细胞的频率。
Afr Health Sci. 2020 Sep;20(3):1264-1272. doi: 10.4314/ahs.v20i3.31.
2
Comparing the frequency of CD33 pSTAT3 myeloid-derived suppressor cells and IL-17 lymphocytes in patients with prostate cancer and benign prostatic hyperplasia.比较前列腺癌和良性前列腺增生患者中 CD33 pSTAT3 髓系来源抑制细胞和 IL-17 淋巴细胞的频率。
Cell Biol Int. 2021 Oct;45(10):2086-2095. doi: 10.1002/cbin.11651. Epub 2021 Jun 29.
3
Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.前列腺癌与良性前列腺增生患者外周血不同淋巴细胞亚群频率的比较研究。
Wien Klin Wochenschr. 2011 Dec;123(23-24):718-25. doi: 10.1007/s00508-011-0096-7. Epub 2011 Nov 23.
4
Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.Engrailed-2 的染色模式改变和表达水平在良性前列腺增生和前列腺癌中预测前列腺疾病的进展。
BMC Cancer. 2020 Jun 15;20(1):555. doi: 10.1186/s12885-020-07049-z.
5
Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.促炎白细胞介素IL-17和IL-17受体在正常、良性增生和恶性前列腺组织中的表达及功能
Prostate. 2003 Aug 1;56(3):171-82. doi: 10.1002/pros.10238.
6
Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.骨桥蛋白 mRNA 剪接变异体在前列腺癌和良性前列腺增生中的表达分析。
Exp Mol Pathol. 2012 Feb;92(1):13-9. doi: 10.1016/j.yexmp.2011.09.014. Epub 2011 Sep 22.
7
Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer.白血病/淋巴瘤相关因子（LRF/Pokemon）在人良性前列腺增生和前列腺癌中的表达。
Exp Mol Pathol. 2011 Apr;90(2):226-30. doi: 10.1016/j.yexmp.2011.01.003. Epub 2011 Jan 18.
8
Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.干扰素-γ及其功能性受体在良性前列腺增生和前列腺癌中的过表达：与c-myc和p53表达的平行关系
Eur Cytokine Netw. 2000 Mar;11(1):119-27.
9
Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.IMP3 在前列腺癌中组织和循环水平的预后价值。
Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4.
10
Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.前列腺癌中的白细胞介素-1（IL-1α和IL-1β）及其受体（IL-1RI、IL-1RII和IL-1Ra）
Cancer. 2004 Apr 1;100(7):1388-96. doi: 10.1002/cncr.20142.

引用本文的文献

1
Analysis of IL10 gene promoter haplotypes and changes in mRNA expression and soluble levels in patients with basal cell carcinoma.基底细胞癌患者中IL10基因启动子单倍型分析及mRNA表达和可溶性水平的变化
Arch Dermatol Res. 2025 Jan 18;317(1):274. doi: 10.1007/s00403-025-03806-x.
2
Endothelial cells in tumor microenvironment: insights and perspectives.肿瘤微环境中的内皮细胞：深入了解和展望。
Front Immunol. 2024 Feb 15;15:1367875. doi: 10.3389/fimmu.2024.1367875. eCollection 2024.
3
Inflammation in Prostate Cancer: Exploring the Promising Role of Phenolic Compounds as an Innovative Therapeutic Approach.

本文引用的文献

1
Epidemiology of prostate cancer in Asian countries.亚洲国家前列腺癌的流行病学
Int J Urol. 2018 Jun;25(6):524-531. doi: 10.1111/iju.13593. Epub 2018 May 8.
2
Dysfunction of CD19CD24CD27 B regulatory cells in patients with bullous pemphigoid.寻常型天疱疮患者中 CD19CD24CD27B 调节性 B 细胞功能障碍。
Sci Rep. 2018 Jan 15;8(1):703. doi: 10.1038/s41598-018-19226-z.
3
B cell regulation in cancer and anti-tumor immunity.癌症中的B细胞调节与抗肿瘤免疫
前列腺癌中的炎症：探索酚类化合物作为一种创新治疗方法的潜在作用。
Biomedicines. 2023 Nov 24;11(12):3140. doi: 10.3390/biomedicines11123140.
4
Effect of IL-10-producing B cells in peripheral blood and tumor tissue on gastric cancer.外周血和肿瘤组织中产生 IL-10 的 B 细胞对胃癌的影响。
Cell Commun Signal. 2023 Nov 9;21(1):320. doi: 10.1186/s12964-023-01174-5.
5
Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer.三级淋巴结构和 B 淋巴细胞：一种有前途的抗癌治疗策略。
Front Immunol. 2023 Aug 9;14:1231315. doi: 10.3389/fimmu.2023.1231315. eCollection 2023.
6
Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?肉瘤中免疫检查点抑制的生物标志物——我们离临床应用还有多远？
Biomark Res. 2023 Aug 23;11(1):75. doi: 10.1186/s40364-023-00513-5.
7
Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy.肿瘤浸润性B细胞在人类癌症中的作用及机制：免疫治疗的新力量
Biomark Res. 2023 Mar 9;11(1):28. doi: 10.1186/s40364-023-00460-1.
8
Immune-Activated B Cells Are Dominant in Prostate Cancer.免疫激活的B细胞在前列腺癌中占主导地位。
Cancers (Basel). 2023 Feb 1;15(3):920. doi: 10.3390/cancers15030920.
9
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.B 细胞和三级淋巴结构作为肿瘤免疫微环境和临床结局的决定因素。
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457. doi: 10.1038/s41571-022-00619-z. Epub 2022 Apr 1.
10
A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy.细胞因子在前列腺癌免疫治疗中的双刃剑作用
Front Oncol. 2021 Nov 16;11:688489. doi: 10.3389/fonc.2021.688489. eCollection 2021.
Cell Mol Immunol. 2017 Aug;14(8):662-674. doi: 10.1038/cmi.2017.35. Epub 2017 Jun 19.
4
A comprehensive review of immunotherapies in prostate cancer.前列腺癌免疫疗法的全面综述。
Crit Rev Oncol Hematol. 2017 May;113:292-303. doi: 10.1016/j.critrevonc.2017.02.026. Epub 2017 Mar 2.
5
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.炎症在前列腺癌进展及治疗反应中的预后价值：一项批判性综述
J Inflamm (Lond). 2016 Nov 25;13:35. doi: 10.1186/s12950-016-0143-2. eCollection 2016.
6
Role of IL-10-producing regulatory B cells in modulating T-helper cell immune responses during silica-induced lung inflammation and fibrosis.IL-10 产生的调节性 B 细胞在二氧化硅诱导的肺炎症和纤维化过程中调节 T 辅助细胞免疫应答中的作用。
Sci Rep. 2016 Jun 29;6:28911. doi: 10.1038/srep28911.
7
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.前列腺微环境中的固有和肿瘤驱动免疫耐受会损害自然杀伤细胞的抗肿瘤活性。
Cancer Res. 2016 Apr 15;76(8):2153-65. doi: 10.1158/0008-5472.CAN-15-1965. Epub 2016 Apr 5.
8
Immunotherapy in prostate cancer: challenges and opportunities.前列腺癌的免疫疗法：挑战与机遇
Immunotherapy. 2016;8(1):69-77. doi: 10.2217/imt.15.101. Epub 2015 Dec 7.
9
CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells.CD19(+)IL-10(+)调节性B细胞影响舌鳞状细胞癌患者的生存率，并诱导静息CD4(+) T细胞分化为CD4(+)Foxp3(+)调节性T细胞。
Oral Oncol. 2016 Feb;53:27-35. doi: 10.1016/j.oraloncology.2015.11.003. Epub 2015 Nov 26.
10
Clinical significance of regulatory B cells in the peripheral blood of patients with oesophageal cancer.食管癌患者外周血中调节性B细胞的临床意义
Cent Eur J Immunol. 2015;40(2):263-5. doi: 10.5114/ceji.2015.52840. Epub 2015 Aug 3.